Stock Events

Stock Events

Aprea Therapeutics 

$0.74
0
+$0.03+4.72% Today

Statistics

Day High
0.74
Day Low
0.74
52W High
-
52W Low
-
Volume
381
Avg. Volume
-
Mkt Cap
4.69M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MayExpected
Q3 2025
Q4 2025
Next
-0.47
-0.4
-0.34
-0.27
Expected EPS
-0.273333
Actual EPS
N/A

Financials

-862.21%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
3.01MRevenue
-25.92MNet Income

Analyst Ratings

$4.10Average Price Target
The highest estimate is 7.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow APRE.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences focuses on oncology, HIV/AIDS, liver diseases, and other areas, directly competing in the cancer treatment space with Aprea Therapeutics.
AMGEN
AMGN
Mkt Cap160.66B
Amgen operates in the biotechnology field focusing on human therapeutics, including treatments for cancer, which competes with Aprea's cancer therapies.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines for cancer and other diseases, making it a direct competitor.
Pfizer
PFE
Mkt Cap140.15B
Pfizer engages in the discovery, development, and manufacture of healthcare products including oncology drugs, competing in the same market as Aprea.
Merck
MRK
Mkt Cap214.76B
Merck is known for its high-quality cancer treatments and research in oncology, positioning it as a competitor in the cancer therapy market.
Novartis
NVS
Mkt Cap237.61B
Novartis focuses on patented medicines for a range of diseases, including cancer, directly competing with Aprea in the oncology sector.
Roche
RHHBY
Mkt Cap258.9B
Roche operates in pharmaceuticals and diagnostics with a strong emphasis on oncology, making it a competitor in cancer treatment.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie works in the discovery, development, and marketing of both biopharmaceuticals and small molecule drugs, including oncology, competing with Aprea.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca operates in several key therapeutic areas including oncology, making it a competitor in the development of cancer treatments.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly and Company focuses on pharmaceuticals in oncology and other areas, competing with Aprea in the cancer treatment market.

About

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Show more...
CEO
ISIN
US03836J2015

Listings

XNAS
US
APRE
BOATS
BOATS
APRE.BOATS

0 Comments

Share your thoughts

FAQ

What is Aprea Therapeutics stock price today?▼
The current price of APRE.BOATS is $0.74 USD — it has increased by +4.72% in the past 24 hours. Watch Aprea Therapeutics stock price performance more closely on the chart.
What is Aprea Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Aprea Therapeutics stocks are traded under the ticker APRE.BOATS.
What is Aprea Therapeutics market cap?▼
Today Aprea Therapeutics has the market capitalization of 4.69M
When is the next Aprea Therapeutics earnings date?▼
Aprea Therapeutics is going to release the next earnings report on May 18, 2026.
What were Aprea Therapeutics earnings last quarter?▼
APRE.BOATS earnings for the last quarter are -0.32 USD per share, whereas the estimation was -0.39 USD resulting in a +17.95% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Aprea Therapeutics revenue for the last year?▼
Aprea Therapeutics revenue for the last year amounts to 3.01M USD.
What is Aprea Therapeutics net income for the last year?▼
APRE.BOATS net income for the last year is -25.92M USD.
When did Aprea Therapeutics complete a stock split?▼
Aprea Therapeutics has not had any recent stock splits.